<DOC>
	<DOC>NCT00393939</DOC>
	<brief_summary>This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Breast cancer with evidence of unresectable locally recurrent, or metastatic disease Her2 negative tumors Patients for whom docetaxel is contraindicated Clinical presentation of inflammatory carcinoma with no other measurable disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Phase 3</keyword>
</DOC>